Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
Emerging Global Leader
Project Information in NIH RePORTER
Multi-target approach to rational design of novel therapeutics for human African trypanosomiasis
Principal Institution
Ahmadu Bello University
Principal Investigator(s) (PI)
Balogun, Emmanuel Oluwadare
Project Contact Information
Email:
oluwadareus@yahoo.com
Year(s) Awarded
2021-2026
Country
Nigeria
Collaborators
Libraries of Small Molecule Repository of Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS)
University of California San Diego (UCSD)
Project Description
Human African trypanosomiasis causes an estimated loss of 1.35 million disability-adjusted life years (DALY) annually, and 65 million people are at risk infection. In addition, the region records an annual loss of US$4.5 billion resulting from millions of cattle, camels, and small ruminants being killed by animal trypanosomiasis. To alleviate such heavy burden created by this disease on Africa, this project is designed to find novel compounds that ablate energy production in the disease pathogens and kill them. The success of this project will generate new classes of safe and effective anti-trypanosoma drug candidates and contribute to the health and economic development of Africa.
Related World Regions / Countries